Bio & Pharma
IVIM Tech supplies biomicroscope to leading US children’s hospital
The company supplies its cutting-edge device to Johns Hopkins after Harvard Medical School last year
By Jul 05, 2023 (Gmt+09:00)
1
Min read
Most Read
Macquarie eyes its 1st Korean data center valued around $722 mn
![close](/images/ico/eyes/close.png)
![open](/images/ico/eyes/open.png)
SK Inc. in talks to sell Pharmteco’s US CDMO plant to Novo Nordisk
![close](/images/ico/eyes/close.png)
![open](/images/ico/eyes/open.png)
S.Korea's LS Materials set to boost earnings ahead of IPO process
![close](/images/ico/eyes/close.png)
![open](/images/ico/eyes/open.png)
Galaxy Ring, new foldables set to steal the show at Samsung Unpacked Paris
![close](/images/ico/eyes/close.png)
![open](/images/ico/eyes/open.png)
POSCO gears up for carbon-free steelmaking with hydrogen
![close](/images/ico/eyes/close.png)
![open](/images/ico/eyes/open.png)
![IVIM Technology's all-in-one intravital microscopy platform IVM-CM3](https://www.kedglobal.com/data/ked/image/2023/07/05/ked202307050016.700x.0.jpg)
South Korea’s IVIM Technology has supplied the world’s first all-in-one intravital microscopy platform that it released last year to a major children’s hospital in the US.
The company on Tuesday said it supplied last month IVM-CM3 to Johns Hopkins Children's Center in Baltimore, Maryland. Sales in the first half of the year reached 1.3 billion won ($1 million), edging out last year’s figure of 1.2 billion won, and three export contracts with China are being pursued.
The purpose of the innovative microscope is to observe living mice and analyze the process of disease development through 3D images divided into single cell units. 3D real-time imaging of proteins and drug molecules allows analysis of drug in vivo delivery and efficacy in the process of biopharmaceutical drug development.
On 2019, IVIM Technology was the first to supply a biomicroscope to Seoul National University and last year, it became the first domestic company to supply research equipment to Harvard Medical School in Boston, namely Harvard Stem Cell Institute.
“We’ll do everything possible to develop technology so that domestic and foreign researchers can identify unknown mechanisms of human diseases and churn out new drugs through biomicroscopy,” IVIM Technology CEO Kim Pil-han said.
Write to Yoo-Rim Kim at youforest@hankyung.com
More to Read
-
-
-
Corporate strategyHyundai Glovis to spend $6.5 billion, seek M&As for expansion
Jun 28, 2024 (Gmt+09:00)
-
Korean chipmakersSouth Korea sets sights on fostering EDA tech to win HBM chip war
Jun 28, 2024 (Gmt+09:00)
-
Comment 0
LOG IN